drugset / Trial / NCT04669171
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Timeline
- Start
- 2021-07-05
- Primary completion
- 2029-05-30
- Completion
- 2034-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EO2463 | Vaccine | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |